Cancer Research Technology
Log in Register
Menu

Cytarabine-resistant (640nM) acute myeloid leukemia (AML) SHI-1 cell line

Invented by Disha Malani , Olli Kallioniemi
Invented at University Of Helsinki

Info

Catalogue Number 159682
Antigen/Gene or Protein Targets Acute myeloid leukemia
Parental Line SHI-1
Tissue Blood
Disease Keywords Cancer, acute myeloid leukemia, cytarabine-resistance, AML, chemotherapy resistance
Model Cancer Model
Relevance Acute myeloid leukaemia (AML) is a cancer of the myeloid line of blood cells, characterised by the rapid growth of abnormal cells that build up in the bone marrow and blood and interfere with normal blood cell production. Cytarabine is a common chemotherapy treatment for AML. Resistance to it in AML cells was shown to be linked to aberrant expression of equilibrative nucleoside transporters (ENT1) and metabolic enzymes deoxycytidine kinase (DCK) and cytosolic 5′-nucleotidase-II (NT5C2). The MOLM-13 cell line was derived from the peripheral blood of a patient at relapse of acute monocytic leukaemia.
Production Details This cell line and the others in this set were generated through long-term treatment of SHI-1 cells with cytarabine. Doses were doubled when the AML cells started to proliferate at an equal rate as theuntreated parental cells.
Conditional No
Research Area Cancer
Growth/Phenotype Keywords cytarabine-resistant
Notes This cell line comes in a set of 4 cytarabine-resistant cell lines, with resistance to increasing doses of cytarabine. This cell line is resistant to 640nM of cytarabine. The parental SHI-1 cell line can be used as a negative control for cytarabine resistance.
Cytarabine resistance was found by the inventors of these cell lines to lead to glucocorticoid sensitivity as long as the cells had a wild- type fms like tyrosine kinase 3 (FLT-3) gene. SHI-1, does contain this wild-type gene and thus is now sensitive to glucocorticoids. The set of 4 MOLM-13 cells which have similarly been made cytarabine resistant (also available via Ximbio) have a mutant form of FLT-3 and thus do not display glucocorticoid sensitivity. See Malani et al, Leukemia volume 31, pages1187–1195(2017) for details.

References

There are 1 reference entries for this reagent.

View All References

References: 1 entry

Malani et al. 2017. Leukemia. 31(5):1187-1195. PMID: 27833094.


Add a reference

References: 1 entry

Malani et al. 2017. Leukemia. 31(5):1187-1195. PMID: 27833094.


Add a reference

Inventor Information

Inventors

Disha Malani

Disha Malani

Olli Kallioniemi

Olli Kallioniemi

Add an inventor